Model-based phase I designs incorporating toxicity and efficacy for single and dual agent drug combinations

Methods and challenges

Sumithra J Mandrekar, Rui Qin, Daniel J. Sargent

Research output: Contribution to journalArticle

29 Citations (Scopus)

Abstract

Novel therapies are challenging the standards of drug development. Agents with specific biologic targets, unknown dose-efficacy curves, and limited toxicity mandate novel designs to identify biologically optimal doses. We review two model-based designs that utilize either a proportional odds model or a continuation ratio model to identify an optimal dose of a single or two-agent combination in a Phase I setting utilizing both toxicity and efficacy data. A continual reassessment method with straightforward dose selection criterion using accumulated data from all patients treated until that time point is employed while allowing for separate toxicity and efficacy curves for each drug in a two-drug setting. The simulation studies demonstrate considerable promise, at least theoretically, in the ability of such model-based designs to identify the optimal dose. Despite such favorable operating characteristics, there are several pragmatic challenges that hinder the routine implementation of such model-based designs in practice. We review and offer practical solutions to potentially overcome some of these challenges. The acceptance and integration of these designs in practice may be quicker and easier if they are developed in concert with a clinical paradigm.

Original languageEnglish (US)
Pages (from-to)1077-1083
Number of pages7
JournalStatistics in Medicine
Volume29
Issue number10
DOIs
StatePublished - May 10 2010

Fingerprint

Drug Combinations
Toxicity
Efficacy
Dose
Drugs
Model-based Design
Model-based
Pharmaceutical Preparations
Patient Selection
Continual Reassessment Method
Proportional Odds Model
Curve
Operating Characteristics
Continuation
Therapy
Paradigm
Design
Simulation Study
Unknown
Target

Keywords

  • Continual reassessment method
  • Dose-finding
  • Efficacy
  • Model-based designs
  • Toxicity
  • Trinary outcome

ASJC Scopus subject areas

  • Epidemiology
  • Statistics and Probability

Cite this

Model-based phase I designs incorporating toxicity and efficacy for single and dual agent drug combinations : Methods and challenges. / Mandrekar, Sumithra J; Qin, Rui; Sargent, Daniel J.

In: Statistics in Medicine, Vol. 29, No. 10, 10.05.2010, p. 1077-1083.

Research output: Contribution to journalArticle

@article{0e49eabee24c458886c2087995d77688,
title = "Model-based phase I designs incorporating toxicity and efficacy for single and dual agent drug combinations: Methods and challenges",
abstract = "Novel therapies are challenging the standards of drug development. Agents with specific biologic targets, unknown dose-efficacy curves, and limited toxicity mandate novel designs to identify biologically optimal doses. We review two model-based designs that utilize either a proportional odds model or a continuation ratio model to identify an optimal dose of a single or two-agent combination in a Phase I setting utilizing both toxicity and efficacy data. A continual reassessment method with straightforward dose selection criterion using accumulated data from all patients treated until that time point is employed while allowing for separate toxicity and efficacy curves for each drug in a two-drug setting. The simulation studies demonstrate considerable promise, at least theoretically, in the ability of such model-based designs to identify the optimal dose. Despite such favorable operating characteristics, there are several pragmatic challenges that hinder the routine implementation of such model-based designs in practice. We review and offer practical solutions to potentially overcome some of these challenges. The acceptance and integration of these designs in practice may be quicker and easier if they are developed in concert with a clinical paradigm.",
keywords = "Continual reassessment method, Dose-finding, Efficacy, Model-based designs, Toxicity, Trinary outcome",
author = "Mandrekar, {Sumithra J} and Rui Qin and Sargent, {Daniel J.}",
year = "2010",
month = "5",
day = "10",
doi = "10.1002/sim.3706",
language = "English (US)",
volume = "29",
pages = "1077--1083",
journal = "Statistics in Medicine",
issn = "0277-6715",
publisher = "John Wiley and Sons Ltd",
number = "10",

}

TY - JOUR

T1 - Model-based phase I designs incorporating toxicity and efficacy for single and dual agent drug combinations

T2 - Methods and challenges

AU - Mandrekar, Sumithra J

AU - Qin, Rui

AU - Sargent, Daniel J.

PY - 2010/5/10

Y1 - 2010/5/10

N2 - Novel therapies are challenging the standards of drug development. Agents with specific biologic targets, unknown dose-efficacy curves, and limited toxicity mandate novel designs to identify biologically optimal doses. We review two model-based designs that utilize either a proportional odds model or a continuation ratio model to identify an optimal dose of a single or two-agent combination in a Phase I setting utilizing both toxicity and efficacy data. A continual reassessment method with straightforward dose selection criterion using accumulated data from all patients treated until that time point is employed while allowing for separate toxicity and efficacy curves for each drug in a two-drug setting. The simulation studies demonstrate considerable promise, at least theoretically, in the ability of such model-based designs to identify the optimal dose. Despite such favorable operating characteristics, there are several pragmatic challenges that hinder the routine implementation of such model-based designs in practice. We review and offer practical solutions to potentially overcome some of these challenges. The acceptance and integration of these designs in practice may be quicker and easier if they are developed in concert with a clinical paradigm.

AB - Novel therapies are challenging the standards of drug development. Agents with specific biologic targets, unknown dose-efficacy curves, and limited toxicity mandate novel designs to identify biologically optimal doses. We review two model-based designs that utilize either a proportional odds model or a continuation ratio model to identify an optimal dose of a single or two-agent combination in a Phase I setting utilizing both toxicity and efficacy data. A continual reassessment method with straightforward dose selection criterion using accumulated data from all patients treated until that time point is employed while allowing for separate toxicity and efficacy curves for each drug in a two-drug setting. The simulation studies demonstrate considerable promise, at least theoretically, in the ability of such model-based designs to identify the optimal dose. Despite such favorable operating characteristics, there are several pragmatic challenges that hinder the routine implementation of such model-based designs in practice. We review and offer practical solutions to potentially overcome some of these challenges. The acceptance and integration of these designs in practice may be quicker and easier if they are developed in concert with a clinical paradigm.

KW - Continual reassessment method

KW - Dose-finding

KW - Efficacy

KW - Model-based designs

KW - Toxicity

KW - Trinary outcome

UR - http://www.scopus.com/inward/record.url?scp=77951528602&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77951528602&partnerID=8YFLogxK

U2 - 10.1002/sim.3706

DO - 10.1002/sim.3706

M3 - Article

VL - 29

SP - 1077

EP - 1083

JO - Statistics in Medicine

JF - Statistics in Medicine

SN - 0277-6715

IS - 10

ER -